You are here:

reslizumab (Cinqaero)

Advice

following a resubmission:

reslizumab (Cinqaero®) is not recommended for use within NHS Scotland.

Indication under review: as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Reslizumab, compared with placebo, decreased the incidence of asthma exacerbations and improved lung function in adult patients with severe eosinophilic asthma. 

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: reslizumab (Cinqaero)
SMC Drug ID: 1233/17
Manufacturer: Teva UK Limited
Indication: as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
BNF Category:
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 11 December 2017

Extra Notes

In April 2017 SMC reviewed a full submission for reslizumab (Cinqaero), however, the SMC advice was withheld pending product availability.  The company subsequently made a resubmission and this was reviewed by SMC in August 2017.  Advice for the original submission was not issued as the product was made commercially available in October 2017. Therefore the advice for the resubmission only is published on the SMC website.

Back